BioNTech Stock Pops on Big Sales Beat

  • Stock Market News
BioNTech Stock Pops on Big Sales Beat
Credit: © Reuters.

Shares of BioNTech (NASDAQ: BNTX ) are up around 1.5% in pre-open Monday after the biotech company reported better-than-expected Q1 EPS and revenue.

The German biotechnology company reported a Q1 EPS of €14.24, up from €4.39 in the year-ago period and the consensus estimates of €8.62. Revenue came in at €6.37, topping the estimated €4.01 billion.

In the first quarter, BioNTech generated €1.16 billion in direct coronavirus vaccine sales in Germany and Turkey, in addition to €603.2 million in sales of products made by BioNTech for its partners.

Commercial revenues in the first quarter included €4.59 billion gross profit share in territories allocated between Pfizer (NYSE: PFE ), BioNTech, and Fosun Pharma (SS: 600196 ) (HK: 2196 ).

For the full fiscal year, BNTX expects capital expenditure in the range of €450 million to €550 million, while analysts were looking for €390.3 million. Coronavirus vaccine revenue is expected to be in the range of €13 billion to €17 billion, compared to the consensus projection of €15.62 billion.

By Senad Karaahmetovic

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or


Related Articles